Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Memorial Sloan Kettering Cancer Center · Cornell University · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,056
total citations
- FWCI
- 125.38
- Percentile
- 100%
- References
- 28
Citations per year
Authors
26- GKGhassan K. Abou‐Alfa
Memorial Sloan Kettering Cancer Center, Cornell University
- TMTeresa Macarulla
Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Universitari
- MJMilind Javle
The University of Texas MD Anderson Cancer Center
- RKRobin Kate Kelley
University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
- SJSam Joseph Lubner
University of Wisconsin Carbone Cancer Center
Topics & keywords
Topics
Keywords
- Refractory (planetary science)
- Medicine
- Placebo
- Double blind
- IDH1
- Oncology
- Chemotherapy
- Internal medicine
No related works found for this paper.